Alectinib

Target: This ligand targets anaplastic lymphoma kinase (ALK) in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for anaplastic lymphoma kinase (ALK). In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings anaplastic lymphoma kinase (ALK) into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• ALK PROTAC Degradation: Alectinib can serve as an ALK-targeting ligand within PROTAC constructs to recruit E3 ligases and drive selective degradation of ALK fusion or mutant kinases. This enables investigation of whether proteolysis produces stronger pathway suppression than kinase inhibition alone, including effects on downstream signaling, cell viability, and resistance mechanisms.

• ALK-Driven Resistance Studies: Incorporating alectinib-derived binding into PROTACs supports mechanistic studies of ALK inhibitor resistance. By degrading the target protein rather than merely blocking ATP binding, researchers can evaluate how degradation alters compensatory signaling, reactivation dynamics, and the emergence of resistant phenotypes under sustained selective pressure.

• Pathway Suppression Mechanism: PROTACs using alectinib as the targeting moiety can be used to dissect temporal and quantitative relationships between ALK loss and pathway shutdown. These studies often include monitoring degradation kinetics, receptor/kinase turnover, and downstream phosphorylation changes to clarify whether complete protein removal yields distinct biological outcomes.

• Comparative Degrader vs Inhibitor: Alectinib-based PROTACs enable head-to-head comparisons against alectinib as a conventional inhibitor. Such experiments assess differences in target engagement duration, degradation-dependent signaling collapse, and phenotypic potency across ALK-positive models, helping define when targeted protein degradation offers advantages for pathway control.

• E3 Ligase Recruitment Optimization: Using alectinib as the ALK-binding element, researchers can systematically vary linker length and E3 ligase recruiters to optimize ternary complex formation and ALK ubiquitination. This application supports mapping design rules for maximizing degradation efficiency, selectivity, and cellular activity while minimizing off-target degradation effects.

Alectinib is an ALK kinase ligand scaffold that can support ALK-directed degrader design. Linker installation should focus on its basic side-chain region while preserving the polycyclic kinase-binding core.

Structure: Alectinib is an ALK kinase ligand scaffold containing a fused benzoindazole/indolinone-like polycyclic core, a nitrile-substituted aryl region, an ethyl substituent, and a morpholine-piperidine side chain. The structure is highly aromatic with a basic solubilizing amine segment.

Reactivity: For ALK-directed PROTAC design, the fused kinase-binding core and nitrile-containing aryl recognition region should be maintained. The morpholine-piperidine side chain is the most plausible solvent-facing region for linker installation in analogs. Alkyl, PEG, amide, carbamate, or tertiary-amine-compatible linkers may be paired with CRBN, VHL, or IAP ligands, but the effect of linker attachment on ALK binding and cellular activity should be validated.